The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VRCA | -54.23% | -95.52% | -46.25% | -98% |
| S&P | +12.57% | +87.93% | +13.44% | +142% |
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $12.70M | 145.4% |
| Gross Profit | $12.21M | 163.4% |
| Gross Margin | 96.11% | 6.6% |
| Market Cap | $49.06M | -84.1% |
| Market Cap / Employee | $0.69M | 0.0% |
| Employees | 71 | -29.0% |
| Net Income | $0.20M | 101.2% |
| EBITDA | $1.71M | 111.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $15.40M | -51.8% |
| Accounts Receivable | $17.37M | 70.2% |
| Inventory | 2.5 | -6.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $25.57M | -43.5% |
| Short Term Debt | $13.32M | 1167.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -106.68% | 45.6% |
| Return On Invested Capital | -145.98% | -59.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.04M | 38.6% |
| Operating Free Cash Flow | -$10.04M | 38.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.94 | -6.52 | -2.19 | -2.81 | -101.37% |
| Price to Sales | 7.37 | 6.23 | 5.84 | 3.42 | -85.96% |
| Price to Tangible Book Value | -19.42 | -9.37 | -41.16 | -26.19 | -101.28% |
| Enterprise Value to EBITDA | -4.58 | -4.44 | -6.91 | 43.19 | -281.75% |
| Return on Equity | -243.3% | -413.0% | -2059.9% | -1546.6% | 590.20% |
| Total Debt | $47.11M | $45.94M | $42.43M | $38.89M | -16.02% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
